Utrecht, Netherlands

Inne Borel Rinkes

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Adenosine Therapeutics, LLC. Active years: 2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Inne Borel Rinkes. Retrieved from https://idiyas.com/inventor/inne-borel-rinkes

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 1 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Inne Borel Rinkes: Innovator in Tumor Treatment

Introduction

Inne Borel Rinkes is a notable inventor based in Utrecht, Netherlands. He has made significant contributions to the field of medical treatment, particularly in addressing recurrent tumor metastases following liver resection.

Latest Patents

Inne holds 1 patent related to a method for treating recurrent tumor metastases. This innovative approach involves the administration of an effective amount of an agonist of adenosine receptors (ARs). His work represents a promising advancement in cancer treatment methodologies.

Career Highlights

Inne Borel Rinkes is associated with Adenosine Therapeutics, LLC, where he applies his expertise to develop new therapeutic strategies. His dedication to improving patient outcomes through innovative treatments is commendable.

Collaborations

Inne collaborates with esteemed colleagues, including Onno Kranenburg and Jarmila Van Der Bilt, who contribute to his research and development efforts.

Conclusion

Inne Borel Rinkes is a pioneering inventor whose work in tumor treatment showcases the potential of innovative medical therapies. His contributions are vital in the ongoing fight against cancer.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…